

Date: August 22, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

Scrip Code: 540359/PARMAX

SUBJECT: INTIMATION REGARDING RECEIPT OF 'IN-PRINCIPLE' APPROVAL UNDER REGULATION 28(1) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR ISSUANCE OF EQUITY SHARES AND WARRANTS ON PREFERENTIAL BASIS

Dear Sir/Madam,

Further to our intimation dated 8th June 2026, we wish to inform you that BSE Limited ('Exchange'/'BSE'), vide its letter no. LOD/PREF/DA/FIP/693/2026-27 dated August 21, 2026, has granted its 'In-Principle' Approval under Regulation 28(1) of the SEBI LODR Regulations for the proposed issuance of the following securities on a preferential basis to the allottees as per Notice of the EGM:

- 31,37,586 (Thirty One Lakh Thirty Seven Thousand Five Hundred and Eighty Six) Equity Shares of face value of Rs. 10/- each at a price of not less than Rs.36.50/- (Rupees Thirty Six and Fifty Paise only) per share; and
- 21,45,145 (Twenty One Lakh Forty Five Thousand One Hundred and Forty Five) Warrants convertible into an equal number of Equity Shares of face value of Rs. 10/- each at a price of not less than Rs.36.50/- (Rupees Thirty Six and Fifty Paise only) per warrant.

The In-Principle approval is subject to necessary compliance under Applicable SEBI regulations.

This is for your information and records.

Kindly take the same on record.

Thanking you,
Yours faithfully,

For Parmax Pharma Limited





Umang Gosalia
DIN: 05153830
Managing Director

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)